Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) have earned an average rating of "Moderate Buy" from the thirteen research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $81.50.

RARE has been the subject of several analyst reports. Wedbush decreased their price objective on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Cantor Fitzgerald reissued an "overweight" rating and issued a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, September 5th. Wells Fargo & Company decreased their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. Morgan Stanley decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. Finally, Canaccord Genuity Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday, August 8th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other news, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the completion of the sale, the executive vice president owned 73,271 shares of the company's stock, valued at approximately $2,283,857.07. The trade was a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.50% of the company's stock.

Institutional Trading of Ultragenyx Pharmaceutical

Several institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in shares of Ultragenyx Pharmaceutical by 28.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock valued at $116,559,000 after acquiring an additional 706,519 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of Ultragenyx Pharmaceutical by 81.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock valued at $77,815,000 after acquiring an additional 965,919 shares in the last quarter. Federated Hermes Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 0.3% during the first quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock valued at $74,419,000 after acquiring an additional 5,400 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock valued at $62,291,000 after acquiring an additional 66,394 shares in the last quarter. Finally, Deutsche Bank AG raised its stake in shares of Ultragenyx Pharmaceutical by 0.5% during the first quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after acquiring an additional 8,385 shares in the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Trading Down 0.7%

RARE opened at $31.45 on Friday. The firm has a market cap of $3.03 billion, a P/E ratio of -5.69 and a beta of 0.21. Ultragenyx Pharmaceutical has a 12 month low of $25.81 and a 12 month high of $57.99. The stock has a 50-day moving average of $29.75 and a 200 day moving average of $33.06.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.10. The company had revenue of $166.50 million during the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm's revenue was up 13.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, research analysts forecast that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.